Inactive Instrument

Press Releases Pardes Biosciences, Inc.

Equities

PRDS

US69945Q1058

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

FS II : Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19 - Form 8-K	27/21/27	PU
PARDES BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	27/21/27	AQ
PARDES BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)	23/21/23	AQ
FS DEVELOPMENT CORP. II : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	23/21/23	AQ
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections	21/21/21	BU
FS II : FSII and Pardes Biosciences Move Towards Merger with the Goal of Tackling COVID-19 Via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections - Form 8-K	21/21/21	PU
FS DEVELOPMENT CORP. II : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	21/21/21	AQ
FS II : Material Event - Form 8-K	17/21/17	PU
FS DEVELOPMENT CORP. II : Other Events (form 8-K)	17/21/17	AQ
FS Development II : Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021 - Form 8-K	01/21/01	PU
FS DEVELOPMENT CORP. II : Other Events, Financial Statements and Exhibits (form 8-K)	01/21/01	AQ
FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021	01/21/01	BU
FS DEVELOPMENT CORP. II Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q/A)	24/21/24	AQ
FS DEVELOPMENT CORP. II : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	24/21/24	AQ
FS DEVELOPMENT CORP. II : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	18/21/18	AQ
FS DEVELOPMENT CORP. II Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	12/21/12	AQ
FS DEVELOPMENT CORP. II : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	10/21/10	AQ
FS Development II : Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections	26/21/26	AQ
FS DEVELOPMENT II : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	16/21/16	AQ
FS Development II : Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections (Form 8-K)	29/21/29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pardes Biosciences, Inc.

Equities

PRDS

US69945Q1058

Press Releases

Filters